The next generation of biotech blockbusters | Thread profile

Denosumab, Ipilimumab, Goliumumab, Motavizumab - FierceBiotech The 2007 rate of new biologic approvals was slow, with only a handful of drugs squeaking through FDA review. But the pace is set to pick up in 2008. According to IMS Health, these biologics could receive FDA approval this year if they don't hit any stumbling blocks. Each of the drugs on this list has the potential for over a ...

Thanks DG

10 Biotechs in Stem Cells that Could Profit Under the Democrats - Seeking Alpha by: Ketan Desai posted on: June 01, 2008 about stocks: ASTM / ATHX / BHRT / CUR / CYTX / GENZ / GERN / OSIR / STEM Democrats and stem cells -- a budding romance. Pundits opine that this will be the year of the Democrats, at least as far as Congress is concerned. Conventional wisdom holds that ...

Wall St. takes a fresh look at biotech, and likes what it sees 4:00 AM, July 23, 2008 In their hunt for a winning growth-stock formula for 2008, some investors have been heading back to the laboratory -- the biotech lab. Biotech shares already were off to a surprisingly strong start in the third quarter even as the rest of the market was sinking. Then came Roche Holding’s offer on Monday ...

Article : The Paradox of Biotechnology Value Investing Genetic Engineering & Biotechnology News - Biotechnology from Bench to Business Jul 1 2008 (Vol. 28, No. 13) The Paradox of Biotechnology Value Investing Assessing Worth Could Be More than Just Conjecture if the Right Tools Are Used David Sable, M.D. On the surface, biotechnology and value do not have much in common. Biotech ...

He who risks nothing gains nothing.　　★★★　　　★★★　★★★★★　★★★★★　　★★★★★★★★★★★ I Love You！　　★★★★★★★★★　　　★★★★★★★　　　　★★★★★　　　　　★★★　　　　　 　★ Welcome to our website for you World of Warcraft Gold,wow gold,Cheap World of Warcraft Gold, WoW Gold , WoW Gold , WoW Gold , WoW Gold , WoW Gold ,